AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

ATENEA Study: Adherence to Creatine-Based Nutritional Supplementation in Estrogen-Depleted Women

Recruitingn/aAges 40 Years - 75 YearsFemaleMargan Biotech
💬

In plain words

What the trial is, and whether it could suit you

This is a prospective, multicenter, observational clinical study conducted under routine clinical practice conditions aimed at describing adherence to a creatine-based nutritional supplement (Creaticare FEM) in estrogen-depleted adult women. Participants will receive the supplement for 12 weeks, and adherence will be assessed as the percentage of doses consumed and the proportion of participants achieving ≥80% adherence. Secondary outcomes include persistence, satisfaction, tolerability, and adherence to recommended physical activity. Exploratory outcomes include changes in muscle strength, body composition, quality of life, joint pain, and skin health.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Biological female sex. * Age ≥40 years. * Estrogen-depleted status, defined as at least one of the following: natural menopause, defined as amenorrhea for ≥12 consecutive months; surgically induced menopause; late perimenopause with elevated FSH according to clinical judgment. * Absence of major comorbidities that would contraindicate use of the nutritional supplement or the recommended physical activity. * No relevant changes in usual treatment during the previous 3 months. * Ability to understand the study information and provide written informed consent. * Willingness to take the nutritional supplement according to the study instructions. * Willingness to follow general physical activity recommendations provided by the investigator. * Willingness and ability to attend the planned visits and complete study assessments through Week 12. Exclusion Criteria: * Initiation or modification of treatment with GLP-1 receptor agonists within the previous 12 weeks. * Presence of musculoskeletal or joint conditions that significantly limit the ability to perform regular physical activity or study-related functional assessments. * Clinically relevant renal or hepatic disease. * Current use of diuretics or potentially nephrotoxic medications. * Known allergy or intolerance to any component of the nutritional supplement. * Participation in another clinical study (nutritional, pharmacological, or interventional) within the previous 3 months. * Any medical condition or social circumstance that, in the investigator's judgment, could interfere with study participation, adherence, or data validity.
💊

What it tests

  • Not listed
📍

Where

4 sites
Clínica Palacios
Madrid, Spain
Menoclinica by Palacios
Madrid, Spain
Ginegetafe
Madrid, Spain
Clinica Palacios Málaga
Málaga, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy